Entrada Therapeutics (NASDAQ:TRDA) Issues Earnings Results, Beats Expectations By $0.11 EPS

Entrada Therapeutics (NASDAQ:TRDA) issued its earnings results on Thursday. The company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.11, FiscalAI reports. The business had revenue of $0.88 million during the quarter, compared to the consensus estimate of $2.92 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%.

Here are the key takeaways from Entrada Therapeutics’ conference call:

• Favorable safety and tolerability at 6 mg/kg: no serious adverse events, mostly mild–moderate AEs (headache most common), normal kidney markers, and all eight Cohort 1 participants have moved into the open?label period.
• Treated participants showed a statistically significant and clinically meaningful improvement in Time To Rise (TTR) velocity versus placebo (mean change 0.08 rises/sec, ~3.5× the MCID), with benefits across most patients despite the small sample size.
• Pediatric PK was ~50% lower than in healthy adult volunteers and adult NHPs, producing modest exon skipping (~2.3% above baseline) and low dystrophin at biopsy (?2.3% then ~6% at day 127), creating exposure and dosing uncertainty that must be addressed.
• Updated modeling using juvenile NHP data projects a dose?dependent, potentially non?linear increase in plasma AUC/exon skipping; management expects double?digit dystrophin in Cohort 2 (12 mg/kg) and higher in Cohort 3, with Cohort 2 dosing underway and results due by year?end 2026.
• Pipeline and timing: Entrada highlights multiple near?term catalysts (Cohort 1 open?label and Cohort 2 readouts by year?end 2026, ELEVATE?45 Cohort 1 mid?2026, partner DM1 data H2 2026) and a reported cash runway into the third quarter of 2027.

Entrada Therapeutics Price Performance

NASDAQ TRDA traded down $9.18 on Thursday, reaching $6.85. 4,118,062 shares of the company’s stock traded hands, compared to its average volume of 210,608. The stock has a market cap of $265.92 million, a PE ratio of -1.98 and a beta of -0.09. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $16.45. The stock has a 50-day simple moving average of $12.82 and a 200 day simple moving average of $10.90.

Insider Transactions at Entrada Therapeutics

In related news, COO Nathan J. Dowden sold 15,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $15.33, for a total transaction of $229,950.00. Following the transaction, the chief operating officer owned 198,588 shares of the company’s stock, valued at approximately $3,044,354.04. This trade represents a 7.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Natarajan Sethuraman sold 25,907 shares of Entrada Therapeutics stock in a transaction on Monday, May 4th. The stock was sold at an average price of $15.39, for a total transaction of $398,708.73. Following the completion of the transaction, the insider owned 216,317 shares in the company, valued at approximately $3,329,118.63. The trade was a 10.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 82,882 shares of company stock worth $1,169,103. 9.49% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP grew its stake in shares of Entrada Therapeutics by 9.5% during the fourth quarter. Wellington Management Group LLP now owns 1,044,758 shares of the company’s stock valued at $10,740,000 after buying an additional 90,339 shares during the last quarter. Millennium Management LLC lifted its stake in shares of Entrada Therapeutics by 391.2% in the 3rd quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock valued at $4,852,000 after acquiring an additional 666,287 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Entrada Therapeutics by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock valued at $4,245,000 after acquiring an additional 42,479 shares during the last quarter. State Street Corp boosted its holdings in Entrada Therapeutics by 2.0% during the 4th quarter. State Street Corp now owns 508,789 shares of the company’s stock valued at $5,230,000 after acquiring an additional 10,174 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its position in Entrada Therapeutics by 14.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 362,786 shares of the company’s stock worth $3,729,000 after acquiring an additional 46,976 shares during the last quarter. 86.39% of the stock is owned by institutional investors.

Key Stories Impacting Entrada Therapeutics

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: Topline Cohort 1 results showed favorable safety/tolerability and a statistically significant improvement in Time?to?Rise velocity (an accepted functional measure) plus early increases in dystrophin and exon skipping — a clinical inflection that validates ENTR?601?44’s early activity. Read More.
• Positive Sentiment: Company has initiated Cohort 2 (12 mg/kg) based on PK modeling and expects additional cohort and open?label data by year?end 2026, creating multiple upcoming clinical catalysts. Read More.
• Neutral Sentiment: Q1 results: EPS loss of $0.95 beat the consensus of $1.06 (smaller loss), but revenue missed expectations ($0.88M vs. est. $2.92M). The EPS beat is modestly supportive, while the revenue miss underlines near?term commercial/partnering headwinds. Read More.
• Negative Sentiment: Financials and cash flow concerns: Q1 net loss widened to $39.7M, collaboration revenue plunged (from $20.6M to $0.9M YoY), and cash declined to ~$255M — though management says runway into Q3 2027, the larger loss and falling collaboration receipts raise funding and execution risk. Read More.
• Negative Sentiment: Market reaction: despite the positive headline, investors sold aggressively (high volume) — likely driven by modest biomarker increases (dystrophin gains were small in absolute terms and juvenile PK was lower than adults), uncertainty about clinical dose/efficacy durability, and the earnings/revenue weakness. Read More.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Oppenheimer raised their price target on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a report on Monday, April 6th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $19.00.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.